Publications by authors named "Frank Mattner"

Claim this Profile
E
Effects of single and combined immunotherapy approach targeting amyloid β protein and α-synuclein in a dementia with Lewy bodies-like model.
Markus Mandler, Edward Rockenstein, Cassia Overk, Michael Mante, Jazmin Florio, Frank Mattner

Alzheimers Dement· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Peptide-based anti-PCSK9 vaccines - an approach for long-term LDLc management.
Gergana Galabova, Sylvia Brunner, Gabriele Winsauer, Claudia Juno, Bettina Wanko, Frank Mattner

PLoS One· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tailoring the antibody response to aggregated Aß using novel Alzheimer-vaccines.
Markus Mandler, Radmila Santic, Petra Gruber, Yeliz Cinar, Dagmar Pichler, Frank Mattner

PLoS One· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials.
Markus Mandler, Elvira Valera, Edward Rockenstein, Harald Weninger, Christina Patrick, Frank Mattner

Acta Neuropathol· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy.
Markus Mandler, Elvira Valera, Edward Rockenstein, Michael Mante, Harald Weninger, Frank Mattner

Mol Neurodegener· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Detection of peri-synaptic amyloid-β pyroglutamate aggregates in early stages of Alzheimer's disease and in AβPP transgenic mice using a novel monoclonal antibody.
Markus Mandler, Edward Rockenstein, Kiren Ubhi, Lawrence Hansen, Anthony Adame, Frank Mattner

J Alzheimers Dis· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AFFITOME® technology in neurodegenerative diseases: the doubling advantage.
Achim Schneeberger, Markus Mandler, Frank Mattner, Walter Schmidt

Hum Vaccin· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The artificial antimicrobial peptide KLKLLLLLKLK induces predominantly a TH2-type immune response to co-injected antigens.
Jörg H Fritz, Sylvia Brunner, Max L Birnstiel, Michael Buschle, Alexander v Gabain, Frank Mattner

Vaccine· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Poly-L-arginine synergizes with oligodeoxynucleotides containing CpG-motifs (CpG-ODN) for enhanced and prolonged immune responses and prevents the CpG-ODN-induced systemic release of pro-inflammatory cytokines.
Karen Lingnau, Alena Egyed, Carola Schellack, Frank Mattner, Michael Buschle

Vaccine· October 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vaccination with poly-L-arginine as immunostimulant for peptide vaccines: induction of potent and long-lasting T-cell responses against cancer antigens.
Frank Mattner, Julia-Kristina Fleitmann, Karen Lingnau, Walter Schmidt, Alena Egyed

Cancer Res· March 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis